Title :

Combining diabetes, sex, and menopause as meaningful clinical features associated with NASH and liver fibrosis in individuals with class II and III obesity: A retrospective cohort study.

Author(s) :

Raverdy, Violetta [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Chatelain, Estelle [Auteur]
Plateformes Lilloises en Biologie et Santé - UAR 2014 - US 41 [PLBS]
Plateforme de bioinformatique et de biostatistique de Lille - PLBS [Bilille]
Lasailly, Guillaume [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Caiazzo, Robert [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Vandel, Jimmy [Auteur]
Plateformes Lilloises en Biologie et Santé - UAR 2014 - US 41 [PLBS]
Verkindt, Hélène [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Marciniak, Camille [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Legendre, Benjamin [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Bauvin, Pierre [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Oukhouya-Daoud, Naima [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Baud, Gregory [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Chetboun, Mikael [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Vantyghem, Marie-Christine [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Gnemmi, Viviane [Auteur]
Miniaturisation pour la Synthèse, l’Analyse et la Protéomique - UAR 3290 [MSAP]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Institut de Pathologie [CHU Lille]
Leteurtre, Emmanuelle [Auteur]
Miniaturisation pour la Synthèse, l’Analyse et la Protéomique - UAR 3290 [MSAP]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Service de pathologie [CHU Lille]
Staels, Bart [Auteur]
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
Lefebvre, Philippe [Auteur]
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
Mathurin, Philippe [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Briend, Guillemette [Auteur]
MOdel for Data Analysis and Learning [MODAL]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Pattou, François [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]

Journal title :

Obesity

Pages :

3066-3076

Publisher :

Wiley

Publication date :

2023-11-21

ISSN :

1930-7381

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Objective:Steatotic liver disease (SLD) is frequent in individuals with obesity. In this study, type 2 diabetes (T2D), sex, and menopausal status were combined to refine the stratification of obesity regarding the risk of ...
Show more >Objective:Steatotic liver disease (SLD) is frequent in individuals with obesity. In this study, type 2 diabetes (T2D), sex, and menopausal status were combined to refine the stratification of obesity regarding the risk of advanced SLD and gain further insight into disease physiopathology.Methods:This study enrolled 1446 participants with obesity from the ABOS cohort (NCT01129297), who underwent extensive phenotyping, including liver histology and transcriptome profiling. Hierarchical clustering was applied to classify participants. The prevalence of metabolic disorders associated with steatohepatitis (NASH) and liver fibrosis (F ≥ 2) was determined within each identified subgroup and aligned to clinical and biological characteristics.Results:The prevalence of NASH and F ≥ 2 was, respectively, 9.5% (N = 138/1446) and 11.7% (N = 159/1365) in the overall population, 20.3% (N = 107/726) and 21.1% (N = 106/502) in T2D patients, and 3.4% (N = 31/920) and 6.1% (N = 53/863) in non-T2D patients. NASH and F ≥ 2 prevalence was 15.4% (33/215) and 15.5% (32/206) among premenopausal women with T2D vs. 29.5% (33/112) and 30.3% (N = 36/119) in postmenopausal women with T2D (p < 0.01); and 21.0% (21/100) / 27.0% (24/89) in men with T2D ≥ age 50 years and 17.9% (17/95) / 18.5% (17/92) in men with T2D < age 50 years (NS). The distinct contribution of menopause was confirmed by the interaction between sex and age with respect to NASH among T2D patients (p = 0.048). Finally, several NASH-associated biological traits (lower platelet count; higher serum uric acid; gamma-glutamyl transferase; aspartate aminotransferase) and liver expressed genes AKR1B10 and CCL20 were significantly associated with menopause in women with T2D but not with age in men with T2D.Conclusions:This study unveiled a remarkably high prevalence of advanced SLD after menopause in women with T2D, associated with a dysfunctional biological liver profile.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

ANR Project :

PreciNASH
EGID Diabetes Pole

Collections :

• Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277

Source :

Harvested from HAL